Opioid Use Disorder Research Study
Researchers at the Medical University of South Carolina are conducting a research study to test a new combination of medicines for outpatient treatment of opioid withdrawal.
Fast Facts
Opioid Use
18+ Years Old
Compensation Provided
Conducted in Charleston, SC
Study Background
UH3-Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Opioid use disorder can be extremely difficult to overcome due to a variety of factors, including severe withdrawal symptoms. In this clinical research study, we are investigating a combination of medications (lofexidine and pregabalin) to treat opioid withdrawal.
Findings from this study will determine whether new approaches to treating withdrawal will improve our ability to use extended-release naltrexone (Vivitrol) as a relapse-prevention medication. If you are currently dependent on opioids and are potentially interested in extended-release naltrexone to prevent relapse, you may be eligible to participate.
Enroll today and help us develop better treatment strategies for individuals like you.
Study Background
UH3-Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Opioid use disorder can be extremely difficult to overcome due to a variety of factors, including severe withdrawal symptoms. In this clinical research study, we are investigating a combination of medications (lofexidine and pregabalin) to treat opioid withdrawal.
Findings from this study will determine whether new approaches to treating withdrawal will improve our ability to use extended-release naltrexone (Vivitrol) as a relapse-prevention medication. If you are currently dependent on opioids and are potentially interested in extended-release naltrexone to prevent relapse, you may be eligible to participate.
Enroll today and help us develop better treatment strategies for individuals like you.
Additional Information
The purpose of this clinical research study is to investigate a new combination of medicines as a possible treatment option (Vivitrol) to reduce withdrawal symptoms in adults with opioid use disorder.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- 18+ years old
- Use opioids regularly or have opioid use disorder
- Potentially interested in extended-release naltrexone (Vivitrol) as a relapse prevention medication
- Able to come to the Medical University of South Carolina located in Charleston, SC for study visits
Exclusion Criteria:
- Currently pregnant or breastfeeding
- Currently receiving opioids for pain management
- Participated in a methadone or buprenorphine treatment program within the last 30 days
If you are eligible to participate, you will be randomized to receive either Lofexidine+Pregabalin OR Lofexidine+Placebo. You will then experience a hybrid of in-person and virtual visits over an 11-day period. You will be required to complete assessments and drug screens and will be responsible for collecting your own blood pressure data multiple times per day and adhering to a medication dosing schedule.
In-person study visits will take place at the research site in Charleston, SC. If needed, we can offer paid Lyft services to participants.
As a participant, you can receive up to $660 for completing the entire study.
There is no cost for you to participate in our research study.
